1174 related articles for article (PubMed ID: 32162319)
1. Immunosuppressive agents for treating IgA nephropathy.
Natale P; Palmer SC; Ruospo M; Saglimbene VM; Craig JC; Vecchio M; Samuels JA; Molony DA; Schena FP; Strippoli GF
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD003965. PubMed ID: 32162319
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive agents for treating IgA nephropathy.
Vecchio M; Bonerba B; Palmer SC; Craig JC; Ruospo M; Samuels JA; Molony DA; Schena FP; Strippoli GF
Cochrane Database Syst Rev; 2015 Aug; (8):CD003965. PubMed ID: 26235292
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome.
von Groote TC; Williams G; Au EH; Chen Y; Mathew AT; Hodson EM; Tunnicliffe DJ
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD004293. PubMed ID: 34778952
[TBL] [Abstract][Full Text] [Related]
4. Non-immunosuppressive treatment for IgA nephropathy.
Tunnicliffe DJ; Reid S; Craig JC; Samuels JA; Molony DA; Strippoli GF
Cochrane Database Syst Rev; 2024 Feb; 2(2):CD003962. PubMed ID: 38299639
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive therapy for IgA nephropathy in children.
Alladin A; Hahn D; Hodson EM; Ravani P; Pfister K; Quinn RR; Samuel SM
Cochrane Database Syst Rev; 2024 Jun; 6(6):CD015060. PubMed ID: 38864363
[TBL] [Abstract][Full Text] [Related]
6. Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
Liu ID; Willis NS; Craig JC; Hodson EM
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31749142
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppressive treatment for proliferative lupus nephritis.
Tunnicliffe DJ; Palmer SC; Henderson L; Masson P; Craig JC; Tong A; Singh-Grewal D; Flanc RS; Roberts MA; Webster AC; Strippoli GF
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD002922. PubMed ID: 29957821
[TBL] [Abstract][Full Text] [Related]
8. Interventions for minimal change disease in adults with nephrotic syndrome.
Azukaitis K; Palmer SC; Strippoli GF; Hodson EM
Cochrane Database Syst Rev; 2022 Mar; 3(3):CD001537. PubMed ID: 35230699
[TBL] [Abstract][Full Text] [Related]
9. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children.
Larkins NG; Liu ID; Willis NS; Craig JC; Hodson EM
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD002290. PubMed ID: 32297308
[TBL] [Abstract][Full Text] [Related]
10. Interventions for focal segmental glomerulosclerosis in adults.
Hodson EM; Sinha A; Cooper TE
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD003233. PubMed ID: 35224732
[TBL] [Abstract][Full Text] [Related]
11. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
[TBL] [Abstract][Full Text] [Related]
12. Interventions for renal vasculitis in adults.
Walters GD; Willis NS; Cooper TE; Craig JC
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD003232. PubMed ID: 31927782
[TBL] [Abstract][Full Text] [Related]
13. Low protein diets for non-diabetic adults with chronic kidney disease.
Hahn D; Hodson EM; Fouque D
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD001892. PubMed ID: 33118160
[TBL] [Abstract][Full Text] [Related]
14. Glucose targets for preventing diabetic kidney disease and its progression.
Ruospo M; Saglimbene VM; Palmer SC; De Cosmo S; Pacilli A; Lamacchia O; Cignarelli M; Fioretto P; Vecchio M; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD010137. PubMed ID: 28594069
[TBL] [Abstract][Full Text] [Related]
15. Low protein diets for non-diabetic adults with chronic kidney disease.
Hahn D; Hodson EM; Fouque D
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD001892. PubMed ID: 30284724
[TBL] [Abstract][Full Text] [Related]
16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
17. Interventions for preventing and treating kidney disease in IgA vasculitis.
Hahn D; Hodson EM; Craig JC
Cochrane Database Syst Rev; 2023 Feb; 2(2):CD005128. PubMed ID: 36853224
[TBL] [Abstract][Full Text] [Related]
18. Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
Hodson EM; Wong SC; Willis NS; Craig JC
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD003594. PubMed ID: 27726125
[TBL] [Abstract][Full Text] [Related]
19. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.
Hahn D; Hodson EM; Hamiwka LA; Lee VW; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD004290. PubMed ID: 31840244
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease.
Natale P; Palmer SC; Navaneethan SD; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2024 Apr; 4(4):CD006257. PubMed ID: 38682786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]